Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

This study is testing a combination of the drug selinexor with two different chemotherapy regimens for people with acute myeloid leukemia (AML) — a blood cancer — that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are 18–60 years old - You have AML that has relapsed or stopped responding to standard chemotherapy - Your AML is not the M3 subtype (APL) - Your disease fits the definition of refractory or relapsed AML per established criteria **You may NOT be eligible if...** - You have AML-M3 (acute promyelocytic leukemia) - Your organ function is too poor to tolerate intensive chemotherapy - You have already exhausted eligibility criteria for the treatments in this study Talk to your doctor to see if this trial is right for you.